Brian Park, PharmD

Drug Information Specialist https://www.renalandurologynews.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Hemodialysis

COVID-19 Antiviral Veklury Approved for Use in Patients With Severe Renal Impairment

Brian Park, PharmD

July 21, 2023

No dosage adjustments are required in patients with any degree of renal impairment.

Prostate Cancer

Lynparza Combo Approved for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

Brian Park, PharmD

June 9, 2023

Lynparza is a poly polymerase inhibitor.

Anemia

Vadadustat Noninferior to Long-Acting ESA for Anemia in Hemodialysis Patients

Brian Park, PharmD

April 10, 2023

Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.

Bladder Cancer

Padcev Plus Keytruda Approved as First-Line Treatment for Urothelial Cancer

Brian Park, PharmD

April 7, 2023

Padcev is a Nectin-4-directed antibody and microtubule inhibitor conjugate; Keytruda is a programmed death receptor-1-blocking antibody.

Prostate Cancer

New Tablet Strength Provides Additional Dosing Option for Erleada

Brian Park, PharmD

April 6, 2023

Erleada (apalutamide), an androgen receptor inhibitor, is now available in a 240mg tablet.

News

Prostate Cancer Treatment Pluvicto Currently in Shortage

Brian Park, PharmD

March 15, 2023

Pluvicto is indicated for patients with PSMA-positive metastatic castration-resistant prostate cancer who have been treated with AR pathway inhibition and taxane-based chemotherapy.

Transplantation

FDA to Review Letermovir for CMV Disease Prevention in Kidney Transplant Recipients

Brian Park, PharmD

February 27, 2023

Letermovir is currently marketed under the brand name Prevymis for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic HSCT.

Tinzaparin may effectively prevent VTE and major bleeding.

Cardiovascular Disease (CVD)

Novel Oral Anticoagulant Fast Tracked for Patients With ESRD and Atrial Fibrillation

Brian Park, PharmD

January 27, 2023

Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.

Chronic Kidney Disease (CKD)

Empagliflozin Under Review for Patients With Chronic Kidney Disease

Brian Park, PharmD

January 25, 2023

The application is supported by data from the phase 3 EMPA-KIDNEY trial, which enrolled more than 6600 adults with CKD at risk of kidney disease progression.

Bladder Cancer

Tecentriq Indication for Previously Untreated Advanced Bladder Cancer Withdrawn

Brian Park, PharmD

December 9, 2022

The decision to withdraw the indication was made based on findings from the subsequent confirmatory phase 3 IMvigor130 trial.

Next post in Bladder Cancer